© Blue Future Holding
By combining Lumic’s technology for automated vaccination with Greenfox Marine’s advanced ultrasound and camera-based systems, the companies are developing a machine that analyses the fish both externally and internally, while simultaneously vaccinating and sorting the fish by gender, health condition, and size.
Hans-Magne Strømme, CEO of Lumic, said in a press release: “This combination enables us to offer fish farmers a tool that increases survival rates and improves growth during the seawater phase. It’s a significant step towards more sustainable production.”
A key element of the collaboration is the integration of ultrasound-based analysis into Lumic’s vaccination machines. Ultrasound is currently primarily used for gender sorting, which is increasingly valued by fish farmers. In addition, Greenfox Marine claims their algorithms can detect risk factors that may affect fish welfare, such as heart function, kidney stones, and spinal deformities.
Erling Aspen, CEO of Greenfox Marine, added: “In addition to gender sorting, our technology evaluates relevant fish health and production parameters through individual monitoring of every fish being vaccinated. This can help optimise both juvenile production and the growth phase after transfer to seawater. We are currently adding a range of new diagnostic functions to our technology platforms.”
Alongside the establishment of this partnership, Blue Future Holding becomes the new majority owner of Lumic, which already owns 97 percent of Greenfox Marine.
“Through this initiative, we can offer fish farmers a unique tool for deploying robust fish into the sea – with greater growth potential and lower mortality. This aligns perfectly with our investment strategy, which has sustainability and fish welfare as core values,” concluded Odd Magne Rødseth, CEO of Blue Future Holding.
